Dog attacks: Victims double since pandemic, surgeon says
An NHS consultant surgeon in West Sussex says he is treating dog attack victims every day.
Similar Posts
Zepbound is off to a strong start, but here’s what Eli Lilly investors are watching
Hopes are sky-high for Eli Lilly’s recently launched weight loss drug Zepbound. Investors will be tuning into the company’s fourth quarter earnings call on Feb. 6, eager to hear more about how that rollout is going. One key statistic will be the number of commercial health insurers providing coverage of the drug, which was approved…
Bristol Myers Squibb to buy Karuna Therapeutics
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after…
Daylesford Organic recall biscuits over moth larvae
Food Standards Agency’s Head of Incidents, Rajwinder Ubhi said: “Daylesford Organic Rye, Spelt & Raisin Crispbreads and Savoury Biscuit Selection have been recalled by the business because the Crispbreads have been contaminated by moth larvae, making the products unsafe to eat.
Humana reports grim 2024 forecast due to soaring medical costs
Signage is displayed on a Humana Inc. office building in Louisville, Kentucky, U.S., on Sunday, Feb. 3, 2019. Humana is scheduled to release earnings figures on February 6. Photographer: Luke Sharrett/Bloomberg via Getty Images Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted on Thursday after the health insurer issued dismal full-year earnings guidance,…
Boehringer Ingelheim, Terns, Viking may join market
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Drugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could…
J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….